Publications

These are publications from work undertaken by Frontier Science (Scotland).

1 2 3 4 5 6
E McFadden;  J Jackson; J Forrest;  2019

Documentation: Essential Documents and Standard Operating Procedures

Principles and Practice of Clinical Trials,  Published online 8 November 2019, doi:10.1007/978-3-319-52677-5_45-1


J Bines;  M Procter; E Restuccia; G Viale; D Zardavas; T Suter; A Arahmani; V Van Dooren; J Baselga; E Clark; J Eng-Wong; RD Gelber; M. Piccart; V Mobus; E. de Azambuja;  2019

Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-positive breast cancer patients

Clinical Breast Cancer,  Published online 5 September 2019, doi:10.1016/j.clbc.2019.06.016


R Hui;  A Pearson; J Cortés; C Campbell; C Poirot; H A Azim; D Fumagalli; M Lambertini; F Daly; A Arahmani; J Pérez-Garcia; P Aftimos; P L Bedard; L Xuereb; E D Scheepers; M Vicente; T Goulioti; S Loibl; S Loi; M-J Pierrat; N C Turner; F Andre; G Curigliano;  2019

Lucitanib for the treatment of HR+/ HER2- metastatic breast cancer: results from the multicohort phase II FINESSE study

Clinical Cancer Research,  16 October 2019, online first, doi:10.1158/1078-0432.CCR-19-1164


E. de Azambuja;  N Ponde; M Procter; P Rastogi; R S Cecchini; M Lambertini; K Ballman; A Moreno-Aspitia; D Zardavas; L Roca; RD Gelber; M Piccart-Gebhart; T Suter;  11 October 2019

A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials

Breast Cancer Research and Treatment,  11 October 2019, online first: doi:10.1007/s10549-019-05453-z


M Procter; 

Simulation Study to Estimate Bias of Treatment Effect in Pain Scores in Diabetic Neuropathy

Pain Medicine,  24 August 2019, online first: doi:10.1093/pm/pnz192


C Kersten;  M G Cameron; A G Bailey; M T Fallon; B J Laird; V Paterson; R Mitchell; S M Fleetwood-Walker; F Daly; S Mjåland;  20 May 2019

Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial

Pain Medicine,  20 May 2019, online first: doi:10.1093/pm/pnz101


J F R Robertson;  Z Jiang; A Di Leo; S Ohno; K I Pritchard; M Ellis; I Bradbury; C Campbell;  May 2019

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

Breast Cancer,  11 May 2019, online first doi:10.1007/s12282-019-00973-4


W P Kirschbrown;  M Kågedal; B Wang; L Lindbom; A Knott; R Mack; S Monemi; I Nijem; S Girish; C Freeman; D Fumagalli; R McConnell; G Jerusalem; C Twelves; J Baselga; G von Minckwitz; J Bines; A Garg;  June 2019

Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

Cancer Chemotherapy and Pharmacology,  Volume 83, Issue No 6, pp. 1147-1158 doi:10.1007/s00280-019-03826-1


Rajiv Mallick;  Stephen Jolles; Hirokazu Kanegane; Dominique Agbor-Tarh; Mikhail Rojavin;  21 November 2018

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: A Pooled Analysis of Six Hizentra® Studies

Journal of Clinical Immunology,  1 - 12, doi:10.1007/s10875-018-0562-3


M Lambertini;  S Martel; C Campbell; S Guillaume; F Hilbers; U Schuehly; L Korde; H A Azim; S Di Cosimo; R C Tenglin; J Huober; J Baselga; A Moreno-Aspitia; M Piccart-Gebhart; RD Gelber; E. de Azambuja; M Ignatiadis;  Published online first 01 June 2018

Pregnancies during and following trastuzumab and/or lapatinib in patients with HER2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials in Cancer

Journal of Clinical Oncology,  Volume 36, No. 15, doi:10.1200/JCO.2018.36.15_suppl.10065


1 2 3 4 5 6